tttttt

Publications:

Tin, M. K., Hakki, T., and Bernhardt, R. Fission yeast as whole-cell test system for the investigation of the aldosterone synthase deficiency-causing mutations. J Steroid Biochem Mol Biol. 124(1-2):31-7. (2011).

Hakki, T., Hübel, K., Waldmann, H., and Bernhardt, R. The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: Old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension. J Steroid Biochem Mol Biol. (Special issue on Targeted Inhibitors). 125(1-2):120-8. (2011).

Petric, S., Hakki, T., Bernhardt, R., and Cresnar, B. Discovery of a steroid 11<alpha>-hydroxylase from Rhizopus oryzae and its biotechnological application. J Biotechnol. 150(3):428-37. (2010).

Hakki, T., Zearo, S., Dragan, C. A., Bureik, M., and Bernhardt, R.Coexpression of redox partners increases the hydrocortisone (cortisol) production efficiency in CYP11B1 expressing fission yeast Schizosaccharomyces pombe. J Biotechnol. 133, 351-9. (2008).

Derouet-Humbert, E., Dragan, C. A., Hakki, T., and Bureik, M. ROS production by adrenodoxin does not cause apoptosis in fission yeast. Apoptosis. 12, 2135-42. (2007).

Hakki, T., and Bernhardt, R. CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacol Ther.111, 27-52. (2006).

Obeid, R., Hakki, T., Jouma, M., and Herrmann, W. The risk ofvenous thromboembolism associated with the factor V Leiden mutation and low B-vitamin status. Clin Chem Lab Med. 41, 1357-62.3. (2003).

Dr. Hakki.de © 2013

Dr. Hakki.de © 2013